The University of Southampton
University of Southampton Institutional Repository

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
1474-175X
321-326
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Harris, Claire
ce357569-f567-477d-88cb-79425d886400
Strasser, Andreas
c9774edf-fa89-481c-8cc4-21f403859700
Scott, Clare L.
9aee7a06-6161-4d3b-8721-c395654dca5f
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Harris, Claire
ce357569-f567-477d-88cb-79425d886400
Strasser, Andreas
c9774edf-fa89-481c-8cc4-21f403859700
Scott, Clare L.
9aee7a06-6161-4d3b-8721-c395654dca5f

Cragg, Mark S., Harris, Claire, Strasser, Andreas and Scott, Clare L. (2009) Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nature Reviews Cancer, (9), 321-326. (doi:10.1038/nrc2615).

Record type: Article

Abstract

Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.

This record has no associated files available for download.

More information

Published date: May 2009

Identifiers

Local EPrints ID: 73221
URI: http://eprints.soton.ac.uk/id/eprint/73221
ISSN: 1474-175X
PURE UUID: bac418ec-774e-41af-aee9-0846ff8658e3
ORCID for Mark S. Cragg: ORCID iD orcid.org/0000-0003-2077-089X

Catalogue record

Date deposited: 03 Mar 2010
Last modified: 14 Mar 2024 02:41

Export record

Altmetrics

Contributors

Author: Mark S. Cragg ORCID iD
Author: Claire Harris
Author: Andreas Strasser
Author: Clare L. Scott

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×